DS-5565 Phase III Study for Post-herpetic Neuralgia

Study Overview
=================
Brief Summary
-----------------
Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo

Detailed Description
-----------------
[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian subjects with PHN receiving DS-5565 versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with PHN.

Official Title
-----------------
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension

Conditions
-----------------
Post-Herpetic Neuralgia

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: DS-5565


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening At screening, a pain scale of ≥ 40 mm Exclusion Criteria: Previous use of neurolytic block

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo (14-weeks) | Drug: Placebo<br>* Placebo<br>|
| Experimental: DS-5565 15 mg Group<br>DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose | Drug: DS-5565<br> <br> * Other names: Mirogabalin;|
| Experimental: DS-5565 20 mg Group<br>DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose | Drug: DS-5565<br> <br> * Other names: Mirogabalin;|
| Experimental: DS-5565 30 mg Group<br>DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose | Drug: DS-5565<br> <br> * Other names: Mirogabalin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Oral Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia | Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary). In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain. | Baseline to Week 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Visual Analog Scale (VAS) Pain From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia | Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome. In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity. | From baseline (Week 14) to Week 66 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-Herpetic Neuralgia, Developmental Phase III